All News

Swedish/Danish cohort study in PsA 17000+ bionaïve 8000+ TNFi & 2000+ other MoA Overall non melanoma skin cancer rate 651 (505 BCC & 87 SCC) TNFi treated pts: HR 1.25 NMSC vs. bionaive (95CI 1.04 to 1.50) HR 1.19 NMSC vs. other MoA (ns) #EULAR2024 @RheumNow AbstOP0150 https://t.co/DVj8l7yFR6

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
“One way to get rid of TDM is to get more drugs, and that’s what we’re doing” - Gertjan Wolbink, the godfather of rheumatology therapeutic drug monitoring (TDM) #EULAR2024 @RheumNow https://t.co/SYM8hjMMPJ

Links:

David Liew drdavidliew ( View Tweet)
TYK2i RCT 290 pts 12 wks in active PSA TAK-279 15mg 30 mg 53% 54% vs PBO 29% ACR 50 15mg 30 mg 26% 26% vs. PBO 10%response PASI 75 30 mg 46% vs. 15m 28% PBO 15% Safety profile acceptable Abstr#OP0138 #EULAR2024 @RheumNow https://t.co/thNuwvUgQp

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Elegant talk of #interferon #gamma in #pyoderma #gangrenosum Vs #PG + #pyogenic #arthritis +#acne #autoinflammatory #syndromes #Papa syn IL18 differences between PG alone and together in syndrome #JAKi May be helpful #EULAR2024 @eular_org @RheumNow @ARD_BMJ @ACR_Journals https://t.co/plYldVdolS

Links:

Janet Pope Janetbirdope ( View Tweet)
In the ‘why therapeutic drug monitoring’ debate, we’ve heard a lot about TDM utility, but the con argument is interesting. Desiree van der Heijde compares TDM to IL-6 levels, which never displaced her DAS then puts up some confronting points. Interesting #EULAR2024 @RheumNow https://t.co/7zomungi3e

Links:

David Liew drdavidliew ( View Tweet)
I have to say: upadacitinib looks very decent for GCA. Not a panacea, but it definitely does something & good safety during trial. Would love to eventually see: - H2H comparative effect vs toci, secukinumab - structural outcomes - long-term safety #EULAR2024 PBA0001 @RheumNow https://t.co/pHZgCKsoA9 https://t.co/5BxCkkLPti

Links:

David Liew drdavidliew ( View Tweet)
#EULAR2024 POS0152 How prevalent is severe refractory #lupus? Multicentre cohort in Asia defined this as SLEDAI-2K=>10 + on GC + immunosuppressant. One in 7 met this definition, assoc w high activity & low T2T achievement. Useful for sample size calc for clinical study @RheumNow https://t.co/bq4gxX7kjI

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 POS0191 Development and validation of plasma biomarkers to predict #lupus flare in the next 12 weeks. Quick turnover results. Need to focus on steps to bring these novel tools from bench to clinical practice @RheumNow https://t.co/64EppGI7bv

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
OP0201- clinical characteristics of pts failing ≥2 b/tsDMARDs D2T RA pts characterised by ⏰ Earlier disease ⏰ Later initiation of DMARD therapy Discontinuation of drugs mainly due to inefficacy regardless of number of drug lines or MOAs used #EULAR2024 @RheumNow

Mrinalini Dey DrMiniDey ( View Tweet)

#EULAR2024 OP0008 Phase 2 #Sjogren RCT Iscalimumab, anti-CD40mAb in two cohorts (1=High systemic activity; 2=High symptom burden but low systemic) showed sustained improvement in ESSDAI & ESSPRI at 48wks in ISC-ISC group, as well as those switched at 24wks from PBO-ISC @RheumNow https://t.co/GuifDHA0lK

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 OP0089 Promising data from Phase 2 RCT on dual blockade depletion & BAFF-R-i, Ianalumab in #lupus. After 24 wks double-blind, sustained response (SRI-4 + Pred ≤5mg/d or ≤ BL dose) was seen in IAN-IAN group while PBO-IAN improved in open label phase at 48wks @RheumNow https://t.co/MUo76ii4vB

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
12-week ARGO Phase 2 trial data of IL-17A- and IL-17F-inhibiting Nanobody sonelokimab delivers rapid onset and robust levels of clinical response, including high-threshold outcomes, compared with placebo in patients with active PsA, with a favorable benefit–risk profile. It met… https://t.co/4wj222FkzP https://t.co/ipUSjKvpuB

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)
OP0140-When should we give #pneumococcal #vaccine to pts starting MTX? Study in RA:PCV13 vaccine given 1 month BEFORE starting MTX leads to higher immunological response at 1m, vs pts vaccinated simultaneously w MTX ⏩Vaccinate patients before starting MTX! @RheumNow #EULAR2024

Mrinalini Dey DrMiniDey ( View Tweet)

When patients say their joints are swollen, what does it mean? Easy to dismiss it as a symptom, but this clinically suspect arthralgia cohort from Leiden shows: - some correlation with MRI/USS findings - predicts RA development still worthwhile! #EULAR2024 POS0609 @RheumNow https://t.co/dw2p5Eo26C

Links:

David Liew drdavidliew ( View Tweet)
#Editors Picks @eular_org @ARD_BMJ @ACR_Journals Can #rheumatologists effectively #dx of #ankylosing #spondylitis? 👍 552 pts - 1/3 axSpA w high certainty Certainty of #dx changed over time 2 features #sacroileitis good #nSAID response #EULAR2024 @RheumNow https://t.co/NN3GZTmgn9

Links:

Janet Pope Janetbirdope ( View Tweet)
#EULAR2024 OP0059 Propensity match scoring of 179 pts w #lupus nephritis in AURA & AURORA1 vs ALMS. Triple therapy (voclosporin + MMF2g/d + low dose GC) led to earlier, greater reduction in proteinuria, & improved safety profile vs dual (MMF3g/d or Cyclo + High dose GC) @RheumNow https://t.co/UdcuaRTtzC

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 OP0017 If one target isn’t enough, why not two! Open label Phase I showed a double-pronged approach, compound BCMA-CD19 CAR Tcells (cCAR) improved clinical response, autoabs elimination & minimal infection in severe refractory #lupus nephritis @RheumNow #EULARBEST https://t.co/6MPHZKxKTB

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Combination of GOL/MTX was not significantly superior in reducing PASDAS-measured disease activity at 24 weeks. First line treatment of early, DMARD naïve PsA with MTX 25 mg/week and CS produced effective disease control. There was low utilisation of bDMARDs at 52 weeks in both… https://t.co/aEg9rw4evM https://t.co/prDtnHm793

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)
I think you can guess why in the USA many Pts with #immunesuppressives In #chronic #diseases? IT IS the 💵 cost of #medications in uninsured pts #EULAR2024 @RheumNow @ACRheum @eular_org A call for #equitable #fair #pharmacare #EULARBEST https://t.co/VRnmKrf3DZ

Links:

Janet Pope Janetbirdope ( View Tweet)
We’ve got better at treating RA over the last 20 years, and it’s genuinely saving lives. Something to be very proud of. Let’s not forget that! 5y mortality from DANBIO 🇩🇰 (still, we still have work to do in seropos RA in men!) #EULAR2024 OP0162 @RheumNow https://t.co/RfvABXhPvS

Links:

David Liew drdavidliew ( View Tweet)
×